Vancouver, BC, Canada - March 27, 2019 - After a rigorous selection process involving hundreds of companies across the globe, Aspect Biosystems has been selected to join 15 growth-stage ventures in the initial Unreasonable FUTURE program. Unreasonable FUTURE is a bold multi-year initiative that will bring together disruptive innovators and entrepreneurs to design a future in which people and technology work side-by-side to solve workplace challenges and unlock human potential everywhere.
The first annual cohort of ventures will include companies creating the future of learning and up-skilling, so underserved youth and those whose jobs are being replaced by technology will find pathways to new opportunities in the digital era. The portfolio also includes entrepreneurs using disruptive technologies to maximize human potential in the workplace of tomorrow. By bringing them together, the goal is to rewrite the narrative of what it means for all humans to thrive in a new, more equitable economy.
Aspect Biosystems is a privately held biotechnology company pioneering microfluidic 3D bioprinting of living, human tissue. Aspect was founded through a collaboration between two internationally-recognized research groups in Engineering and Medicine at the University of British Columbia and has since grown to a company of over 30 scientists, engineers, and business professionals.
“Unreasonable FUTURE is bringing together a hand-picked portfolio of entrepreneurs leveraging advanced technologies to ensure future generations thrive in the new economy,” Daniel Epstein, founder and CEO of Unreasonable Group said. “It’s an honor to have the opportunity to support these outstanding ventures to help design a future that will work for everyone.”
The first Unreasonable FUTURE program will take place from March 27 - April 7, at a private venue outside of San Jose, California. A full list of ventures, mentors, and specialists participating in Unreasonable FUTURE can be found here. Additional details about the partnership and program can be found on the website.
Unreasonable envisions a world in which the most valuable and influential companies are those solving humanity’s most pressing challenges. Through running worldwide immersive programs for growth-stage entrepreneurs, unique partnerships with multinationals, a globally-oriented private equity fund, an extensive international community of serial business leaders as mentors, and advanced storytelling and media activities, Unreasonable is designed to exclusively support entrepreneurs positioned to bend history in the right direction. Currently, Unreasonable works with 162 entrepreneurs who support the jobs of more than 170,000 people and who are actively impacting the lives of over 260 million individuals across more than 180 countries. They have raised over $2.3 billion dollars in funding and generated more than $1.8 billion in revenue. For more, visit www.unreasonablegroup.com.
Aspect Biosystems is a privately held biotechnology company pioneering microfluidic 3D bioprinting of living, human tissue. The company’s proprietary technology is enabling advances in understanding fundamental biology, disease research, development of novel therapeutics, and regenerative medicine. In addition to its internal programs, Aspect is focused on strategically partnering with pharmaceutical and biotechnology companies, as well as academic researchers, to enable the creation of living, human tissues for medical research, therapeutic discovery, and regenerative medicine products. For more, visit www.aspectbiosystems.com.
Natalie Korenic, Marketing & Communications Manager